175 related articles for article (PubMed ID: 33122010)
1. Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach.
Komasaka T; Dressman J
Eur J Pharm Sci; 2021 Feb; 157():105630. PubMed ID: 33122010
[TBL] [Abstract][Full Text] [Related]
2. Biorelevant in vitro Tools and in silico Modeling to Assess pH-Dependent Drug-drug Interactions for Salts of Weak Acids: Case Example Potassium Raltegravir.
Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
J Pharm Sci; 2022 Feb; 111(2):517-528. PubMed ID: 34597624
[TBL] [Abstract][Full Text] [Related]
3. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
4. A physiologically-based drug absorption modeling for orally disintegrating tablets.
Kambayashi A; Kiyota T
Eur J Pharm Biopharm; 2020 Jul; 152():1-9. PubMed ID: 32371153
[TBL] [Abstract][Full Text] [Related]
5. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
Kambayashi A; Blume H; Dressman JB
Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
7. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
Kambayashi A; Dressman JB
J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
[TBL] [Abstract][Full Text] [Related]
8. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
Otsuka K; Wagner C; Selen A; Dressman J
J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
[TBL] [Abstract][Full Text] [Related]
9. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
[TBL] [Abstract][Full Text] [Related]
10. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
11. Drug dissolution and transit in a heterogenous gastric chyme after fed administration: Semi-mechanistic modeling and simulations for an immediate-release and orodispersible tablets containing a poorly soluble drug.
Danielak D; Gajda M; Bołtromiuk T; Sulikowska K; Kubiak B; Romański M
Eur J Pharm Biopharm; 2024 Jul; 200():114341. PubMed ID: 38795785
[TBL] [Abstract][Full Text] [Related]
12. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of disintegration rate is important for predicting the oral absorption of solid dosage forms containing poorly soluble weak base drugs.
Nakamura K; Kambayashi A; Onoue S
Eur J Pharm Biopharm; 2022 Nov; 180():23-32. PubMed ID: 36154905
[TBL] [Abstract][Full Text] [Related]
14. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
Shono Y; Jantratid E; Dressman JB
Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
[TBL] [Abstract][Full Text] [Related]
15. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
16. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
Beloica S; Cvijić S; Bogataj M; Parojčić J
Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
[TBL] [Abstract][Full Text] [Related]
17. PBPK modeling coupled with biorelevant dissolution to forecast the oral performance of amorphous solid dispersion formulations.
Kambayashi A; Kiyota T; Fujiwara M; Dressman JB
Eur J Pharm Sci; 2019 Jul; 135():83-90. PubMed ID: 31125680
[TBL] [Abstract][Full Text] [Related]
18. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling.
Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
Eur J Pharm Sci; 2021 Mar; 158():105656. PubMed ID: 33253885
[TBL] [Abstract][Full Text] [Related]
19. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
Vaidhyanathan S; Wang X; Crison J; Varia S; Gao JZH; Saxena A; Good D
J Pharm Sci; 2019 Jan; 108(1):741-749. PubMed ID: 30439460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
